Get 40% Off
⚠ Earnings Alert! Which stocks are poised to surge?
See the stocks on our ProPicks radar. These strategies gained 19.7% year-to-date.
Unlock full list

Australia to investigate two deaths for possible links to COVID-19 vaccine

Published 29/04/2021, 10:45 am
Updated 29/04/2021, 10:48 am

By Renju Jose

SYDNEY, April 29 (Reuters) - Australia's medicines regulator will investigate two deaths for possible links to the COVID-19 vaccine, raising fresh concerns as the country seeks to accelerate an immunisation programme that has widely missed its initial vaccination targets.

"All reports ... of death following vaccination are reviewed to assess the likelihood that the vaccine contributed to the event or medical condition that led to a fatal outcome," the Therapeutic Goods Administration (TGA) said on Thursday.

Two men died in the country's most populous state of New South Wales (NSW) days after getting their coronavirus vaccine shots, Australian media reported.

A 71-year-old man with several underlying health conditions died days after getting AstraZeneca (NASDAQ:AZN)'s AZN.L vaccine, Seven News reported. A 55-year-old man died eight days after getting his vaccine, a regional newspaper in NSW's northwest town of Tamworth said in a report, citing his family.

The reporting of an adverse event after vaccination does not mean it was caused by the doses, TGA said in an emailed reply. It did not specify when the deaths happened, citing patient confidentiality reasons, or the type of shots they received.

Australia's immunisation drive includes AstraZeneca and Pfizer (NYSE:PFE) PFE.N vaccines but earlier this month authorities abandoned a goal to vaccinate its near 26 million population by the end of 2021 after finding possible links between the AstraZeneca vaccine and blood clots.

Australia, which had banked on the AstraZeneca vaccine for the majority of its shots, recommended the doses should only be given to people above 50 years, throwing its vaccination programme into disarray. weeks ago, the country reported its first death from blood clots linked to the AstraZeneca vaccine after the medicines regulator said a 48-year-old woman's fatality was "likely" linked to the shot. has largely avoided the high COVID-19 numbers seen in other developed countries, with just over 29,700 cases and 910 deaths since the pandemic began, but its vaccination rollout has hit several roadblocks.

More than 2 million total vaccine doses have been administered as of Tuesday, far short of the 4 million pledged by the end of March.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.